Investigational drug · Phase 3
Bofanglutide
Also called: GZR18, Bofanglutida
Not approved by FDA. In 11 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 2 Diabetes Mellitus (T2DM), Obstructive Sleep Apnea (OSA), Obesity/Overweight in Adult.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
11
6 still active
All registered trials
2
Any phase or sponsor naming "Bofanglutide"
First trial start
2024
Dec 30, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Bofanglutide", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 2 Diabetes Mellitus (T2DM)
- Obstructive Sleep Apnea (OSA)
- Obesity/Overweight in Adult
- Obesity & Overweight
- Obesity/Overweight
- Overweight or Obesity
- Obesity and Overweight
Approved drugs for the same conditions: Type 2 diabetes · Obesity and weight management · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "Bofanglutide" as an intervention, largest first.
- BALANCE-DM2 Study of Bofanglutide in Adults With Type 2 DiabetesPivotal-lookingNot yet recruiting
Carnot LaboratoriesIndustry
NCT07628985 · 374 participants (planned) · Start Sep 2026 · Primary completion Oct 2027
Drug: Bofanglutide; Semaglutide · For: Type 2 Diabetes Mellitus (T2DM)
Sites: Mexico City, Mexico; Pachuca, Mexico; Guadalajara, Mexico · 7 sites in all
- BALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or ObesityPivotal-lookingNot yet recruiting
Carnot LaboratoriesIndustry
NCT07622810 · 352 participants (planned) · Start Sep 2026 · Primary completion Dec 2027
Drug: Bofanglutida; Semaglutide · For: Obesity & Overweight
Sites: Guadalajara, Mexico; Morelia, Mexico; Querétaro City, Mexico · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Development and validation of a multiplexed LC-HRMS method for nine GLP-1 receptor agonists and its pharmaceutical application.
Tong LH, Leung KK, Hung CT · J Chromatogr A 2026
- Safety, tolerability, relative bioavailability, pharmacokinetics, and pharmacodynamics of single and multiple doses of the novel oral bofanglutide in healthy Chinese participants.
Hao X, Liu L, Li P, et al. · Diabetes Res Clin Pract 2026
- Weekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.
Liu M, Cheng Z, Lu L, et al. · Ann Intern Med 2026
- Safety and efficacy of GZR18, a long-acting GLP-1 analog, in Chinese patients with type 2 diabetes: A randomized, double-blind, phase 1b/2a trial.
Liu M, Wang X, Li M, et al. · Cell Rep Med 2026
- GZR18, a GLP-1 analog with once-weekly or bi-weekly dosing for body weight management: A randomized, placebo-controlled, phase 1b/2a trial.
Ji L, Gao L, Dong R, et al. · Cell Rep Med 2026
- Corrigendum to "GZR18, a novel long-acting GLP-1 analog, demonstrated positive in vitro and in vivo pharmacokinetic and pharmacodynamic characteristics in animal models" [Europ. J. Pharmacol. 928 (2022) 175107].
Zhang M, Zhang Y, Peng X, et al. · Eur J Pharmacol 2026
Also in development for Type 2 Diabetes Mellitus (T2DM)
- MWN109 1Phase 36 trials
Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
- MWN109 2Phase 36 trials
Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
- MWN109 3Phase 35 trials
Shanghai Minwei Biotechnology Co., Ltd · Overweight , Obesity, Type 2 Diabetes Mellitus (T2DM)
- BGM0504 AdministeredPhase 32 trials
BrightGene Bio-Medical Technology Co., Ltd. · Type 2 Diabetes Mellitus (T2DM)
- AD-233APhase 31 trial
Addpharma Inc. · Type 2 Diabetes Mellitus (T2DM)
- AD-233BPhase 31 trial
Addpharma Inc. · Type 2 Diabetes Mellitus (T2DM)
- AD-233CPhase 31 trial
Addpharma Inc. · Type 2 Diabetes Mellitus (T2DM)
- AD-233DPhase 31 trial
Addpharma Inc. · Type 2 Diabetes Mellitus (T2DM)
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.